Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous Complete Response (AxIn Study).

Next Previous
Trial Profile

Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous Complete Response (AxIn Study).

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Nivolumab (Primary) ; Ipilimumab
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms AxIn Study

Most Recent Events

  • 27 Jan 2024 Trial design presented at the 2024 Genitourinary Cancers Symposium
  • 05 May 2023 Status changed from not yet recruiting to recruiting.
  • 24 Apr 2023 Line of therapy is not clear. Form for Axitinib assumed from RDI.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top